Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

UNLABELLED: All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-ineligible/intolerant and 87 nonresponder patients with chronic HCV genotype 1b infection were enrolled at 24 centers in Japan. Patients received daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 24 weeks. The primary endpoint was sustained virologic response 24 weeks after treatment (SVR24 ). This study is registered with ClinicalTrials.gov (NCT01497834). SVR24 was achieved by 87.4% of…

• BS
  Bristol-Myers Squibb
• G
  GlaxoSmithKline
• GJ
  GlaxoSmithKline Japan
• DS
  Dainippon Sumitomo Pharma
• OP
  Otsuka Pharmaceutical
• TI
  Toray Industries
• MT
  Mitsubishi Tanabe Pharma Corporation
• CP
  Chugai Pharmaceutical
• DS
  Daiichi Sankyo Europe